Evidence map›Paper›PMID 42376234›Full record

ArticleClinical and translational radiation oncology2026

Patient selection and toxicity predictors in proton reirradiation for locoregional breast cancer recurrence.

Molly A Chakraborty, Charlie White, Atif J Khan, Siyu Yang, Zhigang Zhang, Francis Yu, Haibo Lin, Lior Z Braunstein, Diana Roth O'Brien, John J Cuaron and 5 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Molly A ChakrabortyRutgers New Jersey Medical School, 185 S Orange Ave, Newark, NJ, USA.
Charlie WhiteDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 633 3 Ave, NY, New York 10017, USA.
Atif J KhanDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.
Siyu YangNew York Proton Center, 225 East 126 St, NY, New York 10035, USA.
Zhigang ZhangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 633 3 Ave, NY, New York 10017, USA.
Francis YuNew York Proton Center, 225 East 126 St, NY, New York 10035, USA.
Haibo LinNew York Proton Center, 225 East 126 St, NY, New York 10035, USA.
Lior Z BraunsteinDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.
Diana Roth O'BrienDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.
John J CuaronDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.
David M GuttmannDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.
Quincey LaPlantDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.
Simon N PowellDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.
Oren CahlonDepartment of Radiation Oncology, NYU Langone, 160 E 34 St, NY, New York 10016, USA.
J Isabelle ChoiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, New York 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Purpose: Patients with breast cancer isolated local-regional recurrence (iLRR) can benefit from salvage reirradiation (reRT) to provide durable control and prevent further progression. Conformal radiation techniques like pencil beam scanning (PBS) proton beam therapy (PBT) may improve the reRT therapeutic ratio by limiting cumulative dose and improving target region dose delivery. Materials and methods: Consecutive patients between 8/2019-9/2025 treated with PBS-PBT reRT for breast cancer iLRR with prior dose overlap were identified. Clinicopathologic, treatment, and outcomes details were collected. Associations between clinical/treatment factors and time to recurrence and grade (G) ≥2 adverse events (AEs) were evaluated with Fine-Gray models and logistic regression, respectively. Correlations between DVH metrics and late AEs were assessed using Kruskal-Wallis and Wilcoxon rank sum tests. Results: Seventy patients were identified with median first course (C1), reRT course (C2), and cumulative doses of 53, 50, and 106Gy(RBE), respectively. During C2, 82.2% received comprehensive nodal irradiation. Median follow-up was 30 months. Two- and three-year rates of any recurrence were 14% and 17%, and OS were 100% and 95%, respectively. Maximum acute G2 and G3 AEs occurred in 50% and 7%, and late G2 and G3 AEs in 34% and 10%, respectively. Rib fractures developed in 21.1% and were associated with C1 and C2 chest wall D200cc and C1 rib D10cc. Conclusion: In the largest experience of PBT reRT for breast cancer iLRR to date, we report promising disease control and limited severe AEs despite a high-risk patient cohort. We provide dose metrics that can serve as the foundation for reRT dose constraints and be further refined in future reRT investigations.

Indexed as

Breast cancerLocoregional recurrenceProton therapyReirradiation

Identifiers

PMID42376234
PMCPMC13312024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.